QGEN
NYSEQiagen N.V.
Price$46.12-0.37 (-0.80%)
01:30 PM07:45 PM
News · 26 weeks29-17%
2026-04-192026-10-11
Mix1390d
- Other5(38%)
- Dividends2(15%)
- Leadership2(15%)
- Analyst2(15%)
- Earnings1(8%)
- SEC Filings1(8%)
Latest news
25 items- PRQIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against TuberculosisGlobal TB Summit brings together international experts as persistent disease burden and funding pressures challenge progress against tuberculosis QuantiFERON-TB Gold Plus detects tuberculosis (TB) infection as an aid to identify people eligible for preventive treatment while supporting clinical evaluation of suspected TB disease More than a decade of QIAGEN-supported education connects clinicians, laboratories, researchers, advocates and public health leaders QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) will bring together tuberculosis experts from around the world for the Global TB Clinical and Educational Summit from October 13-16 as a persistent disease burden and gr
- PRQIAGEN Expands AI-Powered Bioinformatics for Research and Drug DiscoveryNew IPA Investigator lets researchers ask biological questions in natural language and examine the scientific evidence behind the results New QIAGEN Discovery Platform extends AI into drug discovery workflows QIAGEN builds on more than 25 years of biomedical knowledge, with QDI tools used by around 150,000 users QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced new artificial intelligence (AI) capabilities to help researchers analyze complex biological and genomic data faster while keeping the scientific evidence behind the results visible. The expansion includes IPA Investigator, a new AI research companion for QIAGEN Ingenuity Pathway Analysis (IPA), and
- ANALYSTQiagen upgraded by Barclays with a new price targetBarclays upgraded Qiagen from Equal Weight to Overweight and set a new price target of $55.00
- PRQIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection PanelBloodstream infections can trigger sepsis, a life-threatening response to infection; about 1.7 million U.S. adults develop sepsis each year, contributing to at least 350,000 deaths New QIAstat-Dx test identifies 13 gram-negative bacterial targets and 18 antibiotic resistance markers in about one hour Complete QIAstat-Dx bloodstream infection menu combines two complementary panels and covers 33 pathogen targets and 28 antibiotic resistance markers QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstream infection portfolio following clearance of a new panel by the U.S. Food and Drug Admin
- PRQIAGEN Launches QIAmini to Automate Small-Batch Sample PreparationCompact system offers research laboratories a time-saving and cost-efficient way to automate work still done by hand Reduction in hands-on time of over 80% compared with manual sample processing Third new sample preparation system launched in 2026 expands automation portfolio from small research labs to high-throughput research and clinical testing QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the launch of QIAmini, a compact automated sample preparation system designed to give research laboratories a time-saving and cost-efficient alternative to processing samples by hand. QIAmini is designed primarily for academic laboratories and other research custo
- PRQIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing BoardQIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that it will hold an Extraordinary General Meeting of Shareholders on November 6, 2026, at 2:00 p.m. CET. Shareholders will be asked to vote on the appointment of Jonathan M. Pratt to the QIAGEN Managing Board after he joined QIAGEN as Chief Executive Officer on September 1, 2026. Subject to shareholder approval, Jon Pratt would join Roland Sackers, Chief Financial Officer, as the two members of QIAGEN’s Managing Board. Shareholders will also be asked to vote on the discharge of Thierry Bernard for his service as a member of the Managing Board through September 1, 2026, when he stepped down as Chief Executive Office
- ANALYSTUBS resumed coverage on Qiagen with a new price targetUBS resumed coverage of Qiagen with a rating of Neutral and set a new price target of $47.00
- SECSEC Form 6-K filed by Qiagen N.V.6-K - QIAGEN N.V. (0001015820) (Filer)
- PR10x Genomics Wins Patent Infringement Verdict Against Parse BiosciencesJury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challengePLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (NYSE:QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025. The patents are exclusively licensed from Roche Sequencing Solutions. The jury also rejected Parse's challenges to the validity of the patents, finding al
- PRQIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid ExtractionNew IVD automation platform standardizes nucleic acid extraction across diverse assay workflows with improved productivity, sample traceability and process safety Builds on more than 3,300 cumulative placements of the established QIAsymphony platform while using the same QIAsymphony kits and consumables Supports high-growth applications such as liquid biopsy QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinic
- PRQIAGEN Appoints Jonathan M. Pratt as Chief Executive OfficerJon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall To assume CEO role on September 1, 2026, succeeding Thierry Bernard QIAGEN reaffirms outlook for the third quarter and full-year 2026; strategic review continues QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. Jon Pratt most recently served as President and C
- PRQIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection PanelQIAstat-Dx BCID GPF Plus AMR Panel detects 20 pathogen targets and 10 antimicrobial resistance markers from positive blood cultures in about one hour FDA clearance marks QIAGEN's entry into U.S. bloodstream infection testing and establishes the first member of a planned QIAstat-Dx BCID panel family Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting about 1.7 million adults annually in the U.S., underscoring the need for rapid detection QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for blood
- PRQIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year OutlookQ2 2026 results: Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline Growth pillars deliver about 5% CER growth, led by Sample technologies, QIAcuity and QDI; QuantiFERON sales rise slightly amid lower U.S. immigration testing demand Adjusted operating income margin of 29.4%, maintaining a high level of profitability Diluted EPS of $0.50; adjusted diluted EPS of $0.62 on a reported and CER basis, above the outlook for at least $0.60 CER H1 2026 operating cash of $301 million remains at a strong level compared with H1 2025 Full-year 2026 outlook reaffirmed fo
- PRQIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora OutbreakMore than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis cases reported across the United
- PRQIAGEN N.V. to Release Results for Q2 2026 and Hold WebcastQIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026. Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 769 9200 UK: +44 (0)20 7769 6464 GER: +49 (0)69 254 99300 Conference ID: 2545624 To avoid waiting time, please join the event co
- PRQIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in EuropeNew CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers from positive blood cultures Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))
- ANALYSTQiagen downgraded by Berenberg with a new price targetBerenberg downgraded Qiagen from Buy to Hold and set a new price target of $45.50
- ANALYSTKepler initiated coverage on Qiagen with a new price targetKepler initiated coverage of Qiagen with a rating of Hold and set a new price target of $38.60
- ANALYSTQiagen upgraded by Morgan Stanley with a new price targetMorgan Stanley upgraded Qiagen from Equal-Weight to Overweight and set a new price target of $42.00
- PRQIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and BiopharmaPlanned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areas Expanded Cell and Gene Therapy offerings and workflow automation capabilities strengthen the QIAcuity digital PCR ecosystem New software capabilities support standardized analysis and reporting across digital PCR workflows QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across li
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Qiagen N.V.SCHEDULE 13G/A - QIAGEN N.V. (0001015820) (Subject)
- PRQIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus OutbreakTwo custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories QIAGEN's broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts
- PRQIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflowsNew AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface Natural-language experience helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information Expands QIAGEN's digital ecosystem with AI-driven workflow support embedded directly into the customer experience QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the global launch of QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify suitable products, access technical information and man
- PRQIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIACollaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms, therapeutic targets and biomarkers are identified Graph-based AI approach designed to help researchers explore mechanisms, therapeutic targets and biomarkers with greater speed, context and confidence Initial pilot programs available to select pharmaceutical and biotechnology partners, with broader availability in future stages following validation QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insigh
- PRQIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General MeetingCo-founder and former CEO Dr. Metin Colpan to become Honorary Chairman of the Supervisory Board after deciding not to stand for re-election Robert McMahon nominated for election to Supervisory Board as part of ongoing renewal process, with seven of eight proposed members having joined since 2021 40% increase in annual dividend proposed to $0.35 per share, reflecting continued commitment to increasing returns to shareholders Additional share repurchase authorizations, including authorization for further open-market share repurchases and a new $200 million synthetic share repurchase Thierry Bernard to stand for re-election as Managing Board member until a new CEO has been app
QGEN FAQ
7 questionsWhat does Qiagen N.V. do?
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid...Where does QGEN stock trade?
Qiagen N.V. (QGEN) is listed on NYSE.What sector and industry is QGEN in?
Qiagen N.V. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Qiagen N.V. go public?
Qiagen N.V. (QGEN) completed its IPO in 2026.What are analysts saying about QGEN?
Qiagen N.V. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight on 2026-10-06. Recent price targets range from $3860.00 to $4700.00.What companies are similar to QGEN?
Notable peers in the same industry include TMO (Thermo Fisher Scientific Inc), ILMN (Illumina Inc.), BIO (Bio-Rad Laboratories Inc.). Compare QGEN side-by-side with any of them on Quantisnow.How can I track QGEN on Quantisnow?
Quantisnow aggregates Qiagen N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QGEN to receive live email and push alerts on every new disclosure.